PLX Nov 2024 1.000 call
| Previous close | 0.6000 |
| Open | 0.3000 |
| Bid | 0.2500 |
| Ask | 2.6000 |
| Strike | 1.00 |
| Expiry date | 2024-11-15 |
| Day's range | 0.3000 - 0.3000 |
| Contract range | N/A |
| Volume | |
| Open interest | 45 |
PR NewswireProtalix BioTherapeutics to Host In-Person Investor Day to Discuss Current Treatment Landscapes and Clinical Results for Fabry Disease and Uncontrolled Gout
Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell based protein expression system, today announced that it will host an in-person investor day at the Lotte Palace New York Hotel in New York on Wednesday, June 26, 2024 at 8:30 a.m. Eastern Daylight Time (EDT).
- PR Newswire
Protalix BioTherapeutics to Present at the 2024 BIO International Convention
Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell based protein expression system, announced today that Dror Bashan, its President and Chief Executive Officer, will present at the upcoming 2024 BIO International Convention June 3 - 6, 2024, in San Diego, California. Mr. Bashan will provide senior biotech executives, busi
- GuruFocus.com
Protalix BioTherapeutics Inc (PLX) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
Despite a dip in revenue, Protalix BioTherapeutics progresses with promising clinical trials and maintains a robust cash reserve.
